Stockreport

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2...

Denali Therapeutics Inc.  (DNLI) 
Last denali therapeutics inc. earnings: 8/6 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.denalitherapeutics.com
PDF SOUTH SAN FRANCISCO, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of the [Read more]